SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$12.76
Market Cap
$2.51B
52W High
$15.88
52W Low
$4.23
ADV30
10,760,267
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
| Jun 2025 | 0 | — | -6,873,000 | -6,601,000 | 32,305,000 | 25,297,000 | 6,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,165,000
Investing CF
$0
Financing CF
$106,865,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,395,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,463,000
Pretax Income TTM
$-29,457,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | — | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | — | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | — | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | — | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,690,000
NetIncome TTM
$-30,482,000
OpCashFlow TTM
$0
Assets (Latest)
$19,432,000
Forward EPS
$-0.12
Max Pain — expiry 2026-07-17
max pain strike: $10.00 · spot: $12.76 · call oi: 54,030 · put oi: 29,739
Expected Move to 2026-07-17:
±$2.85
(22.34%) —
implied range
$9.91 –
$15.61
· ATM straddle on $13.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | $2.50B | $28.38 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.53B | $17.84 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.45B | $41.23 | — |
| PHVS | Pharvaris N.V. | $2.45B | $35.07 | — |
| NRIX | Nurix Therapeutics, Inc. | $2.38B | $23.06 | — |
News headlines (Yahoo Finance, 1h cache)
Here’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026
2026-07-09 10:38 · Yahoo
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
2026-07-09 04:38 · Yahoo
SLS Stock In The Spotlight As CEO Pushes Back On Regal Trial Criticism – ‘Let’s Separate The Noise From The Data’
2026-07-08 17:03 · Yahoo
SLS Stock Logs 2-Day Losing Streak: Mixed Institutional Bets Emerge Ahead Of Key AML Trial Update
2026-07-08 06:13 · Yahoo
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick
2026-07-07 05:15 · Yahoo
This Little-Known Stock Has Surged 550% in the Past Year
2026-07-06 16:40 · Yahoo
SLS Stock Notches 3-Week Winning Run: MassMutual Opens Tiny Stake Ahead Of Key AML Readout
2026-07-06 01:27 · Yahoo
SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success
2026-07-02 03:26 · Yahoo
SELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial Data
2026-07-01 08:20 · Yahoo
SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out?
2026-07-01 05:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.